New Products: Foundation Medicine's FoundationOne; Omixon's Target | GenomeWeb

Foundation Medicine has launched FoundationOne, its targeted sequencing-based cancer test, which screens for mutations in 200 cancer-related genes. The test is offered out of the company's CLIA certified laboratory on the Illumina HiSeq 2000 with a turnaround time of 21 days. The test must be ordered by a physician and is used to match genomic alterations with a targeted therapy or clinical trial.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.